Petroutsas to lead U.S. commercial operations at Astellas
Plus: Evan Ballantyne named CFO at Hansa and updates from BostonGene and InflaRx
Astellas Pharma Inc. (Tokyo:4503) hired Michael Petroutsas as head of U.S. commercial at its Astellas Pharma US Inc. unit. Petroutsas was SVP, U.S. specialty and oncology business at GSK plc (LSE:GSK; NYSE:GSK). He succeeds Mark Reisenauer, who is leaving at the end of March.
Evan Ballantyne will become CFO of Hansa Biopharma AB (SSE:HNSA) on March 1, succeeding Donato Spota. Ballantyne was SVP, CFO at Gain Therapeutics Inc. (NASDAQ:GANX)...